Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Radiation technologies play a significant role in contemporary human healthcare and extensively used for therapeutic and diagnostic applications in healthcare, especially in cancer care in the country ...

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial.

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) ...

Seven randomized phase 2/3 studies (ENZA-p, PSMAfore, TheraP, VISION, SPLASH, and others) contributed 2526 patients; 1365 received 177Lu-PSMA-617 and 1161 received standard therapies. Progression-free ...

Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...

PALM DESERT, Ca., February 17, 2026 — New research highlighting the growing potential of radiopharmaceutical therapies (RPT) to improve outcomes for people with cancer will be presented at the ...